SLV308 for Treatment of Patients With Early Parkinson's Disease

Summary

This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Timeline

Start

2006-06

Primary completion

2007-12

Completion

2007-12

Outcome

Met primary endpoint

paper Pardoprunox showed a significant benefit over placebo in the primary efficacy variable PMID 21542016 ↗

Publications

• Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord. 2011 Jul;26(8):1464-76. doi: 10.1002/mds.23590. Epub 2011 May 3.

Drugs

Indications